Dingell, Stupak praise firms for following AMA guidelines

Share this content:
Reps. John Dingell and Bart Stupak, who chair the Committee on Energy and Commerce and the Oversight and Investigations Subcommittee thereof, respectively, praised Merck, Schering-Plough, Pfizer and J&J for agreeing to follow AMA guidelines regarding the use of docs in ads and to not advertise off-label uses of drugs, but complained of the firms' refusal to commit to four more advertising conditions they'd requested, most notably a two-year moratorium on ads for new drugs. Instead, the four firms agreed to wait six months. 
Share this content:
Scroll down to see the next article